Author:
Haidar Sam H.,Makhlouf Fairouz,Schuirmann Donald J.,Hyslop Terry,Davit Barbara,Conner Dale,Yu Lawrence X.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations, March 2003.
2. L. B. Sheiner. Bioequivalence Revisited. Stat. Med. 11:1777–1788 (1992).
3. R. Schall, and H. G. Luus. On Population and Individual Bioequivalence. Stat. Med.
12:1109–1124 (1993).
4. S. H. Haidar, B. Davit, M-L. Chen, D. Conner, L. M. Lee, Q. H. Li, R. Lionberger, F. Makhlouf, D. Patel, D. J. Schuirmann, and L. X. Yu. Bioequivalence approaches for highly variable drugs and drug products. Pharm. Res.
25:237–241 (2008).
5. S. D. Patterson, N. M.-D. Zariffa, T. H. Montague, and K. Howland. Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products. Eur. J. Pharm. Sci.
57:663–670 (2001).
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献